Literature DB >> 23567218

Metastatic colorectal cancer outcome and fatty liver disease.

Antoine Brouquet1, Bernard Nordlinger.   

Abstract

Various factors are reported to affect the risk of local recurrence after resection of colorectal liver metastases. This article discusses the findings of a recent study that investigated the effect of fatty liver disease on the risk of recurrence.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23567218     DOI： 10.1038/nrgastro.2013.53

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

1.  Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).

Authors:  Halfdan Sorbye; Murielle Mauer; Thomas Gruenberger; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Eric Van Cutsem; Werner Scheithauer; Manfred P Lutz; Bernard Nordlinger
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

2.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.

Authors:  Jean-Nicolas Vauthey; Timothy M Pawlik; Dario Ribero; Tsung-Teh Wu; Daria Zorzi; Paulo M Hoff; Henry Q Xiong; Cathy Eng; Gregory Y Lauwers; Mari Mino-Kenudson; Mauro Risio; Andrea Muratore; Lorenzo Capussotti; Steven A Curley; Eddie K Abdalla
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

3.  Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.

Authors:  Dietmar Tamandl; Markus Klinger; Sandra Eipeldauer; Beata Herberger; Klaus Kaczirek; Birgit Gruenberger; Thomas Gruenberger
Journal:  Ann Surg Oncol       Date:  2010-09-16       Impact factor: 5.344

4.  Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases.

Authors:  Z Z R Hamady; M Rees; F K Welsh; G J Toogood; K R Prasad; T K John; J P A Lodge
Journal:  Br J Surg       Date:  2013-01-28       Impact factor: 6.939

5.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

6.  High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model.

Authors:  Michael Nathan VanSaun; In Kyu Lee; Mary Kay Washington; Lynn Matrisian; David Lee Gorden
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

7.  Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases.

Authors:  Benjamin Angliviel; Stéphane Benoist; Christophe Penna; Mostafa El Hajjam; Sophie Chagnon; Catherine Julié; Alain Beauchet; Philippe Rougier; Bernard Nordlinger
Journal:  Ann Surg Oncol       Date:  2009-02-28       Impact factor: 5.344

8.  Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases.

Authors:  Antoine Brouquet; Stéphane Benoist; Catherine Julie; Christophe Penna; Alain Beauchet; Philippe Rougier; Bernard Nordlinger
Journal:  Surgery       Date:  2009-02-23       Impact factor: 3.982

9.  Impact of steatosis on perioperative outcome following hepatic resection.

Authors:  David A Kooby; Yuman Fong; Arief Suriawinata; Mithat Gonen; Peter J Allen; David S Klimstra; Ronald P DeMatteo; Michael D'Angelica; Leslie H Blumgart; William R Jarnagin
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.267

10.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321
  10 in total
  14 in total

1.  NOD-like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLD.

Authors:  Koichiro Ohashi; Zhijun Wang; Yoon Mee Yang; Sandrine Billet; Wei Tu; Michael Pimienta; Suzanne L Cassel; Stephen J Pandol; Shelly C Lu; Fayyaz S Sutterwala; Neil Bhowmick; Ekihiro Seki
Journal:  Hepatology       Date:  2019-05-23       Impact factor: 17.425

2.  Icaritin activates JNK-dependent mPTP necrosis pathway in colorectal cancer cells.

Authors:  Chunxian Zhou; Zhengrong Chen; Xingsheng Lu; Hao Wu; Qunying Yang; Dongfeng Xu
Journal:  Tumour Biol       Date:  2015-10-01

3.  miR-659-3p is involved in the regulation of the chemotherapy response of colorectal cancer via modulating the expression of SPHK1.

Authors:  Shuyuan Li; Ying Fang; Hai Qin; Wenzheng Fu; Xipeng Zhang
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

4.  Aqueous Oldenlandia diffusa extracts inhibits colorectal cancer cells via activating AMP-activated protein kinase signalings.

Authors:  Pei-Hua Lu; Min-Bin Chen; Chao Ji; Wen-Ting Li; Mu-Xin Wei; Mian-Hua Wu
Journal:  Oncotarget       Date:  2016-07-19

5.  The preclinical analysis of TW-37 as a potential anti-colorectal cancer cell agent.

Authors:  Shun Lei; Yao Ding; Yun Fu; Shuang Wu; Xiong Xie; Cancan Wang; Houjie Liang
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

6.  MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase.

Authors:  Weidong Xu; Huayong Jiang; Fuli Zhang; Junmao Gao; Jun Hou
Journal:  Oncol Lett       Date:  2017-03-23       Impact factor: 2.967

7.  Preclinical study of cinobufagin as a promising anti-colorectal cancer agent.

Authors:  Xing-Sheng Lu; Yin-Biao Qiao; Ya Li; Bo Yang; Min-Bin Chen; Chun-Gen Xing
Journal:  Oncotarget       Date:  2017-01-03

8.  NPC-26 kills human colorectal cancer cells via activating AMPK signaling.

Authors:  Zhen Zhao; Li Feng; Jiqin Wang; Deshan Cheng; Mei Liu; Meirong Ling; Weiping Xu; Keyu Sun
Journal:  Oncotarget       Date:  2017-03-14

9.  AMPK-autophagy inhibition sensitizes icaritin-induced anti-colorectal cancer cell activity.

Authors:  Chunxian Zhou; Jun Gu; Gang Zhang; Da Dong; Qunying Yang; Min-Bin Chen; Dongfeng Xu
Journal:  Oncotarget       Date:  2017-02-28

10.  The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.

Authors:  Chen Li; Jian-Feng Cui; Min-Bin Chen; Chao-Ying Liu; Feng Liu; Qian-De Zhang; Jian Zou; Pei-Hua Lu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.